A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer
Clinical trial NCT03155009 · COMPLETED
Trial details
- NCT number
- NCT03155009
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-07-10
- Primary completion
- 2019-09-26
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.